Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases

CONCLUSIONS: This study demonstrates the safety of neoadjuvant combination tremelimumab and durvalumab prior to CRC liver resection. Evidence for T and B cell activation following this therapy was seen in pMMR mCRC.PMID:33811152 | DOI:10.1158/1078-0432.CCR-21-0163

Source: Clinical Cancer Research - April 3, 2021 Category: Cancer & Oncology Authors: Preeti Kanikarla Marie Cara Haymaker Edwin R Parra Young Uk Kim Rossana Lazcano Swati Gite Daniele Lorenzini Ignacio I Wistuba Rebecca S S Tidwell Xiaofei Song Wai Chin Foo Dipen M Maru Yun Shin Chun P Andrew Futreal Bryan Kee David Menter Luisa M Solis C Source Type: research